Related Experiment Video

Updated: May 16, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Overview of M-LP/MPV17L, a novel atypical PDE and possible target for drug development

Reiko Iida1, Toshihiro Yasuda2

  • 1Molecular Neuroscience Unit, School of Medical Sciences, University of Fukui, Fukui, 910-1193, Japan.

European Journal of Pharmacology
|April 3, 2025
PubMed

Insights

M-LP/MPV17L protein, initially found in mouse kidney, has cyclic nucleotide phosphodiesterase activity. Its deficiency in mice leads to improved glucose tolerance and cardiac hypertrophy, suggesting therapeutic potential.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • M-LP/MPV17L (Mpv17-like protein) is a novel protein identified in mouse kidney.
  • Previous studies suggested M-LP/MPV17L's role in mitochondrial DNA maintenance and cell defense against mitochondrial dysfunction.
  • The molecular mechanism of M-LP/MPV17L remained largely unknown.

Purpose of the Study:

  • To review the molecular characteristics, expression regulation, cellular functions, and disease relevance of M-LP/MPV17L.
  • To explore M-LP/MPV17L as a potential drug development target.
  • To summarize findings from M-LP/MPV17L-knockout (KO) models.

Main Methods:

  • CRISPR-Cas9 technology was used to generate M-LP/MPV17L-knockout (KO) cells.
  • M-LP/MPV17L-knockout (KO) mice were generated to study in vivo phenotypes.
  • Analysis of cyclic nucleotide phosphodiesterase (PDE) activity and cAMP/PKA signaling pathways.

Main Results:

  • M-LP/MPV17L exhibits cyclic nucleotide phosphodiesterase (PDE) activity, despite lacking typical PDE structural motifs.
  • M-LP/MPV17L is a key component in cAMP/cAMP-dependent protein kinase A (PKA) signaling.
  • M-LP/MPV17L deficiency in mice resulted in beta-cell hyperplasia, improved glucose tolerance, and cardiac hypertrophy.

Conclusions:

  • M-LP/MPV17L possesses unique PDE activity and plays a significant role in cellular signaling pathways.
  • M-LP/MPV17L deficiency leads to distinct physiological phenotypes, highlighting its importance in metabolic and cardiac health.
  • M-LP/MPV17L represents a promising target for therapeutic interventions in metabolic and cardiovascular diseases.
Keywords:
Cardiac hypertrophyCyclic nucleotide phosphodiesteraseDiabetesMpv17-like proteincAMP/PKA signaling

More Related Videos

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.3K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.1K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
104
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
124